The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Apnex Medical touted a $10 million funding infusion from New Enterprise Associates, planning on using the money to support its ongoing clinical studies.
The St. Paul, Minn.-based respiratory devices company is amid clinical studies for its Hypoglossal Nerve Stimulation System for use in patients with obstructive sleep apnea.
The FDA approved a new Medtronic (NYSE:MDT) stent for peripheral arterial disease and green-lighted a pivotal clinical trial of a so-called “artificial pancreas” for Type I diabetics.
The pair of regulatory wins follow a decision that didn’t go Medtronic’s way, after an FDA panel last week recommended against approval of one of its cardiac ablation devices for a type of atrial fibrillation.
St. Jude Medical Inc. (NYSE:STJ) enrolled the first patient into its pan-European study of early interventions of irregular heartbeat.
St. Jude can enroll more than 3,000 patients across 200 centers in Europe, including locations in Belgium, the Czech Republic, Denmark, France, Germany, Italy, the Netherlands, Poland, Spain, Switzerland and the United Kingdom.
By Thomas Lee
Apnex Medical Inc., a St. Paul, Minn.-based start-up developing technology to treat obstructive sleep apnea, named Charles McKhann as its new CEO.
McKhann, who previously served as a global vice president of marketing for Boston Scientific Corp.’s (NYSE:BSX) cardiac rhythm management division, replaces founder and executive director Robert Atkinson. While at Johnson & Johnson (NYSE:JNJ), McKhann helped oversee the global launch of Cypher, the first drug-eluting stent.
